Study of Novel Treatment Combinations in Patients With Lung Cancer
Public ClinicalTrials.gov record NCT05633667. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this platform clinical trial is to test how well novel treatment combinations work in participants with lung cancer. Substudy-01 will compare the different novel combinations versus standard of care in participants with metastatic (cancer that has spread) non-small-cell lung cancer (NSCLC) who have not been treated before. Substudy-02 will compare the different novel combination versus standard of care in participants with cancer that has progressed after receiving previous treatment for metastatic NSCLC. Substudy-03 will compare the different novel combinations versus standard of care in participants with resectable stage II-III NSCLC. The primary objectives of this study are: Substudy-01 and Substudy-02: To evaluate the objective response rate (ORR) assessed per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). Substudy-03: To evaluate the efficacy of treatment combinations based on complete pathological response (pCR) rate.
Study identification
- NCT ID
- NCT05633667
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 192 participants
Conditions and interventions
Conditions
Interventions
- Zimberelimab (ZIM) Drug
- Domvanalimab (DOM) Drug
- Sacituzumab govitecan-hziy (SG) Drug
- Etrumadenant (ETRUMA) Drug
- Carboplatin Drug
- Cisplatin Drug
- Pemetrexed Drug
- Paclitaxel Drug
- Nab-paclitaxel Drug
- Docetaxel Drug
- Nivolumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 15, 2023
- Primary completion
- Aug 31, 2029
- Completion
- Aug 31, 2029
- Last update posted
- May 31, 2026
2023 – 2029
United States locations
- U.S. sites
- 11
- U.S. states
- 6
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology Associates,Substudy-02 | Tucson | Arizona | 85711 | — |
| Fort Wayne Medical Oncology and Hematology, Inc.,Substudy-03 | Fort Wayne | Indiana | 46845 | — |
| Baptist Health Lexington,Substudy-03 | Lexington | Kentucky | 40503 | — |
| Washington University School of Medicine - Siteman Cancer Center,Substudy-01 | St Louis | Missouri | 63110 | — |
| Washington University School of Medicine - Siteman Cancer Center,Substudy-02 | St Louis | Missouri | 63110 | — |
| Washington University School of Medicine - Siteman Cancer Center,Substudy-03 | St Louis | Missouri | 63110 | — |
| Washington University School of Medicine - Siteman Cancer Center | St Louis | Missouri | 63110 | — |
| Oncology Hematology Care Clinical Trials, LLC,Substudy-01 | Cincinnati | Ohio | 45242 | — |
| Oncology Hematology Care Clinical Trials, LLC,Substudy-02 | Cincinnati | Ohio | 45242 | — |
| Oncology Associates of Oregon, PC,Substudy-01 | Eugene | Oregon | 97401 | — |
| Oncology Associates of Oregon, PC,Substudy-02 | Eugene | Oregon | 97401 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 78 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05633667, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 31, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05633667 live on ClinicalTrials.gov.